187 related articles for article (PubMed ID: 9760024)
1. Evaluation of cannabimimetic effects of structural analogs of anandamide in rats.
Wiley JL; Ryan WJ; Razdan RK; Martin BR
Eur J Pharmacol; 1998 Aug; 355(2-3):113-8. PubMed ID: 9760024
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats.
Di Marzo V; Berrendero F; Bisogno T; González S; Cavaliere P; Romero J; Cebeira M; Ramos JA; Fernández-Ruiz JJ
J Neurochem; 2000 Apr; 74(4):1627-35. PubMed ID: 10737621
[TBL] [Abstract][Full Text] [Related]
3. Cannabis: discrimination of "internal bliss"?
Wiley JL
Pharmacol Biochem Behav; 1999 Oct; 64(2):257-60. PubMed ID: 10515300
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys.
Wiley JL; Golden KM; Ryan WJ; Balster RL; Razdan RK; Martin BR
Pharmacol Biochem Behav; 1997 Dec; 58(4):1139-43. PubMed ID: 9408225
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs.
Adams IB; Ryan W; Singer M; Thomas BF; Compton DR; Razdan RK; Martin BR
J Pharmacol Exp Ther; 1995 Jun; 273(3):1172-81. PubMed ID: 7791088
[TBL] [Abstract][Full Text] [Related]
6. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and behavioral evaluation of alkylated anandamide analogs.
Adams IB; Ryan W; Singer M; Razdan RK; Compton DR; Martin BR
Life Sci; 1995; 56(23-24):2041-8. PubMed ID: 7776830
[TBL] [Abstract][Full Text] [Related]
8. Discriminative stimulus effects of anandamide in rats.
Wiley J; Balster R; Martin B
Eur J Pharmacol; 1995 Mar; 276(1-2):49-54. PubMed ID: 7781695
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes.
Wiley JL; Martin BR
Chem Phys Lipids; 2002 Dec; 121(1-2):57-63. PubMed ID: 12505690
[TBL] [Abstract][Full Text] [Related]
10. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance.
Mallet PE; Beninger RJ
Life Sci; 1998; 62(26):2431-9. PubMed ID: 9651110
[TBL] [Abstract][Full Text] [Related]
11. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds.
Sugiura T; Kodaka T; Nakane S; Miyashita T; Kondo S; Suhara Y; Takayama H; Waku K; Seki C; Baba N; Ishima Y
J Biol Chem; 1999 Jan; 274(5):2794-801. PubMed ID: 9915812
[TBL] [Abstract][Full Text] [Related]
12. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.
Järbe TU; Lamb RJ; Lin S; Makriyannis A
Psychopharmacology (Berl); 2001 Aug; 156(4):369-80. PubMed ID: 11498713
[TBL] [Abstract][Full Text] [Related]
13. Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats.
Rubino T; Viganò D; Costa B; Colleoni M; Parolaro D
J Neurochem; 2000 Dec; 75(6):2478-84. PubMed ID: 11080200
[TBL] [Abstract][Full Text] [Related]
14. Anandamide- and delta9-tetrahydrocannabinol-evoked arachidonic acid mobilization and blockade by SR141716A [N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4 -methyl-1H-pyrazole-3-carboximide hydrochloride].
Shivachar AC; Martin BR; Ellis EF
Biochem Pharmacol; 1996 Mar; 51(5):669-76. PubMed ID: 8615904
[TBL] [Abstract][Full Text] [Related]
15. Functional role of high-affinity anandamide transport, as revealed by selective inhibition.
Beltramo M; Stella N; Calignano A; Lin SY; Makriyannis A; Piomelli D
Science; 1997 Aug; 277(5329):1094-7. PubMed ID: 9262477
[TBL] [Abstract][Full Text] [Related]
16. Task specificity of cross-tolerance between Delta9-tetrahydrocannabinol and anandamide analogs in mice.
Wiley JL; Smith FL; Razdan RK; Dewey WL
Eur J Pharmacol; 2005 Mar; 510(1-2):59-68. PubMed ID: 15740725
[TBL] [Abstract][Full Text] [Related]
17. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide.
Pertwee RG; Stevenson LA; Griffin G
Br J Pharmacol; 1993 Dec; 110(4):1483-90. PubMed ID: 8306090
[TBL] [Abstract][Full Text] [Related]
18. Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices.
Ameri A; Wilhelm A; Simmet T
Br J Pharmacol; 1999 Apr; 126(8):1831-9. PubMed ID: 10372827
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture.
Kim D; Thayer SA
J Neurosci; 2001 May; 21(10):RC146. PubMed ID: 11319244
[TBL] [Abstract][Full Text] [Related]
20. Effects of cannabinoid receptor agonists on immunologically induced histamine release from rat peritoneal mast cells.
Lau AH; Chow SS
Eur J Pharmacol; 2003 Mar; 464(2-3):229-35. PubMed ID: 12620517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
